AML: making residual disease more measurable
Blood
.
2022 Aug 4;140(5):415-417.
doi: 10.1182/blood.2022017138.
Authors
Maria Teresa Voso
1
,
Francesco Buccisano
1
Affiliation
1
University of Rome Tor Vergata.
PMID:
35925646
DOI:
10.1182/blood.2022017138
No abstract available
Publication types
Editorial
Comment
MeSH terms
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / therapy
Neoplasm Recurrence, Local*
Neoplasm, Residual
Prospective Studies